Company Name | iPS Portal, Inc |
---|---|
Founded | July 31, 2014 |
Managing Directors | CEO Masakazu Kobayashi |
Address | Louis Pasteur Center for Medical Reserch, Bldg., 103-5 Tanaka Monzen-cho , Sakyo-ku, Kyoto 606-8225, Japan |
Capital | 1.868 billion Yen (capital stock of 951,600,000 Yen, and capital reserve of 917,000,000 Yen) |
Number of employees | 30 (as of the end of January 2021) |
Scientific Advisory Board | Kenji Osafune Professor, Center for iPS Cell Research and Application, Kyoto University Shimon Sakaguchi, Honorary Professor, Osaka University, and Honorary Professor, Kyoto University Kohji Nishida, Professor & Chairman, Department of Ophthalmology, Graduate School of Medicine, Osaka University |
---|---|
Management Advisory Board | Motoshige Ito, Honorary Professor, The University of Tokyo, and Professor, Gakushuin University Richard C. Koo, Chief Researcher, Center for Strategic Management & Innovation, Nomura Research Institute |
Consultants | Hideo Saji, Honorary Professor, Kyoto University and Director, Kyoto University Research Administration Office Masahiro Kino-oka, Professor, Graduate School of Engineering Osaka University |
Pharmaceutical Affairs Consultants | Shin Kawamata, Director & Chairman, Research & Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation at Kobe Zen-ichi Mohri, Regenerative Medicine Advisor for Development |
iPS Portal Inc. began operations in September 2014, following the transfer of non-patent related operations of iPS Academia Japan, Inc. At the time of its establishment, iPS Portal Inc. focused on contract testing of iPS cells in efforts to promote the broad use of iPS cell technology. We also provide support for start-up companies related to Cell-Technology, and have been involved in the establishment and operation of Raymei, Inc., a corneal regenerative medicine company since 2016 and Houjou, Inc., a company that aims to protect endangered species and to commercialize fertility treatments since 2020. In January 2021, we moved our headquarters and laboratory to a new location, marking the next stage of our business.We will continue to contribute to the development of the life science field by supporting iPS cells and other Cell-Technology-based research and business from both technology and business perspectives, and by providing higher value-added services.